Balchem Corp. 10-Q Summary: Period Ended September 30, 2010
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Balchem Corporation, an accelerated filer incorporated in Maryland. The report covers the three and nine-month periods ended September 30, 2010. Balchem develops, manufactures, and distributes specialty performance ingredients for food, nutritional, pharmaceutical, animal health, and medical device sterilization industries. The company operates through three segments: Specialty Products; Food, Pharma & Nutrition; and Animal Nutrition & Health.
Key Financial Metrics
| Metric (in thousands) | 9 Months Ended Sep 30, 2010 | 9 Months Ended Sep 30, 2009 | 3 Months Ended Sep 30, 2010 |
|---|---|---|---|
| Net Sales | $185,271 | $160,254 | $63,910 |
| Gross Margin | $56,763 (30.6%) | $50,001 (31.2%) | $20,233 (31.7%) |
| Operating Income | $35,953 (19.4%) | $29,898 (18.7%) | $13,018 (20.4%) |
| Net Earnings | $23,861 | $19,819 | $8,493 |
| Diluted EPS | $0.81 | $0.69 | $0.29 |
| Cash from Operations | $29,331 | $39,065 | N/A |
| Cash & Equivalents (Sep 30, 2010) | $65,447 | ||
| Total Debt (Current + Long-term) | $5,426 | ||
| Working Capital | $89,777 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15.6% year-over-year for the nine months ended September 30, 2010, driven by volume growth across all segments. The Animal Nutrition & Health segment contributed the largest absolute increase ($16.1M), while Food, Pharma & Nutrition saw the highest percentage growth (20.0%).
- Profitability: Net earnings rose 20.4% to $23.9M. Operating margins improved to 19.4% from 18.7% despite higher raw material costs.
- Acquisition Activity: The company acquired a marketer and distributor of propylene oxide for $4.7M, contributing to sales growth in the Specialty Products segment.
- Cost Pressures: Gross margin percentage declined slightly for the nine-month period (30.6% vs 31.2%) due to increased petro-chemical raw material costs and a force majeure event affecting a key supplier.
- Capital Expenditures: Capital spending increased significantly to $6.0M from $2.1M in the prior year period, reflecting facility investments and the acquisition.
Outlook, Risks, and Management Commentary
- Outlook: Management continues to focus on volume growth through new product launches and capitalizing on choline production capabilities. The company is actively pursuing additional acquisition candidates.
- Liquidity: Cash and cash equivalents increased to $65.4M. The company paid off its $29M Term Loan in full during the period. It maintains a $6.0M Revolving Facility and a European Revolving Facility of approximately $4.1M, both currently with no outstanding balances.
- Risks: Key risks include exposure to commodity price fluctuations (petro-chemicals), foreign currency exchange rates (specifically the strength of the U.S. Dollar impacting Euro-denominated sales), and potential environmental liabilities related to the Verona, Missouri facility (though the company believes remediation is complete and it is indemnified).
- Unusual Items: Operating expenses included costs related to the Aberco acquisition, recruiting, and relocation. A force majeure event from a supplier impacted raw material costs.
Investor Verification Checklist
- Verify the sustainability of volume growth in the Animal Nutrition & Health segment given the stabilization of poultry production levels mentioned in the report.
- Monitor the impact of rising petro-chemical raw material costs on future gross margins, particularly in the Animal Nutrition segment.
- Confirm the integration progress and revenue contribution of the recent propylene oxide distributor acquisition.
- Review the status of the Verona, Missouri Superfund site remediation and the enforceability of the indemnification from the prior owner.
- Assess the company's ability to maintain liquidity and fund future acquisitions without increasing leverage, given the current low debt levels.